6. パーキンソン病 Parkinson disease Clinical trials / Disease details
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
Showing 1 to 7 of 7 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02857244 (ClinicalTrials.gov) | November 2016 | 25/7/2016 | A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients | A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients | Parkinson's Disease | Drug: Duloxetine;Drug: Donepezil;Drug: Modafinil | University of Chicago | NULL | Withdrawn | 18 Years | 100 Years | All | 0 | Phase 2 | United States |
2 | JPRN-jRCTs061180028 | 11/05/2015 | 26/02/2019 | Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine ... | A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetineagainst pain associa ... | Parkinson's disease;D010300 | The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule. The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. Dur ... | Ando Rina | NULL | Complete | 20 years old | None | Both | 50 | Phase 2 | Japan |
3 | JPRN-UMIN000016734 | 2015/04/01 | 01/04/2015 | The evaluation of duloxetine effect for the parkinsonism and gait freezing | The evaluation of duloxetine effect for the parkinsonism and gait freezing - The evaluation of effect of duloxetine and parkinsonism The evaluation of duloxetineeffect for the parkinsonism and gait freezing - The evaluation of effect ... | Parkinson's disease | Drug ; Duloxetine Duraion; SEP012014-AUG312016 Doseage; 20mg/day or 40mg/day Times; one time per day P.O. Drug ; Duloxetine Duraion; SEP012014-AUG312016 Doseage; 20mg/day or 40mg/day Times; one time per day P. ... | Department of Neurology, Juntendo University School of Medicine | NULL | Complete: follow-up complete | 20years-old | 85years-old | Male and Female | 30 | Not selected | Japan |
4 | JPRN-UMIN000016893 | 2014/09/22 | 01/04/2015 | A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression. A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetineagainst pain associa ... | A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetine against pain associated with Parkinson's disease with depression. - Pain reduction in PD patients with depression: double blind, randomized clinical trial of duloxetine. A double-blind, randomized clinical trial to evaluate the efficacy of Duloxetineagainst pain associa ... | PD patients | The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule. The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. During the Titration Period (2 weeks), all subjects will be started on 1 capsule (10mg or placebo). During the Maintenance Period (10 weeks), subjects will take 2 capsules. Subjects who are unable to increase their dose can stay at 1 capsule. The treatment groups consist of an active treatment arm (40mg/day Duloxetine) and a placebo arm. Dur ... | Ehime University HospitalDept. of Clinical pharmacology and Neurology | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 50 | Phase 2 | Japan |
5 | NCT01504178 (ClinicalTrials.gov) | May 2011 | 30/12/2011 | Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease | Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease | Parkinson's Disease | Drug: duloxetine;Drug: placebo of duloxetine;Drug: injection of apomorphine;Drug: injection of placebo of apomorphine;Drug: L-Dopa;Drug: injection of placebo of L-Dopa Drug: duloxetine;Drug: placebo of duloxetine;Drug: injection of apomorphine;Drug: injection of place ... | University Hospital, Toulouse | French Parkinson Association | Completed | 30 Years | 70 Years | All | 28 | Phase 3 | France |
6 | EUCTR2010-018650-12-FR (EUCTR) | 13/07/2010 | 06/05/2010 | Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien - DOULOX Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient ... | Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient Parkinsonien - DOULOX Evaluation du système noradrénergique dans l’altération de la perception douloureuse chez le patient ... | maladie de Parkinson MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's maladie de Parkinson MedDRA version: 12.1;Level: LLT;Classification code 10013113;Term: Disease Park ... | Trade Name: CYMBALTA Product Name: duloxetine Trade Name: APOKINON Product Name: apomorphine Trade Name: MODOPAR Product Name: levodopa Trade Name: MOTILIUM Product Name: dompéridone Trade Name: CYMBALTA Product Name: duloxetine Trade Name: APOKINON Product Name: apomorphine Trade Name: ... | CHU de Toulouse | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | France | |||
7 | NCT00437125 (ClinicalTrials.gov) | March 2007 | 16/2/2007 | Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease | An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease An Open Label Pilot Study on the Tolerability of Duloxetinein the Treatment of Depressed Patients Wi ... | Major Depressive Disorder;Idiopathic Parkinson Disease | Drug: Duloxetine hydrochloride | Eli Lilly and Company | NULL | Completed | 30 Years | 75 Years | All | 151 | Phase 4 | Italy |